The head of a World Health Organization-led team probing the origins of Covid-19 said bats remain a likely source and that transmission of the virus via frozen food is a possibility that warrants further investigation, but he ruled out a lab leak.

The U.S. Food and Drug Administration gave Emergency Use Authorization (EUA) to a Covid-19 test developed by Roche that measures antibodies within the blood.

Researchers at Massachusetts Institute of Technology (MIT) developed an artificial intelligence (AI) model able to detect asymptomatic Covid-19 cases by identifying differences in the sounds of coughs between healthy and infected people.

Cytokinetics’ stocks plummeted after the company released topline results from a Phase III cardiovascular clinical trial with partners Amgen and Servier in which the secondary endpoint to prove potential to save lives failed. 

Sanofi and Regeneron said results from a Phase III open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in adults and adolescents with moderate-to-severe asthma.

The U.S. Food and Drug Administration approved Bristol Myers Squibb’s Onureg (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission or CR with incomplete blood count recovery following intensive induction chemotherapy and who are not able to complete intensive curative therapy.

Researchers at the University of California, San Francisco (UCSF) synthesized a molecule inspired by llama antibodies called nanobodies that could neutralize SARS-CoV-2, the virus that causes Covid-19.

Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill Covid-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as the company assesses the plasma-based treatment in a Phase III study.

According to several studies, the risk of contracting COVID-19 or developing a serious case of the disease may be greater depending on blood type.

CSL Behring is attempting to make a difference in the pandemic in various ways, including harnessing the power of antibodies from the blood of recovered COVID-19 patients.